Viking Therapeutics stock forecast: VK2735 Phase III progress

Viking Therapeutics is developing VK2735 for obesity, with two Phase III VANQUISH trials fully enrolled and maintenance-dosing results due this quarter. Explore third-party VKTX price targets and technical analysis. Past performance is not a reliable indicator of future results.

By Dan Mitchell10:39 (UTC), 23 September 2026

Viking Therapeutics Stock Forecast | VK2735 Phase III Progress — Source: Shutterstock

Viking Therapeutics, Inc. (VKTX) traded near $29.89 at 2.02pm UTC on 16 September 2026, within the day’s $29.76–$30.75 range. Past performance is not a reliable indicator of future results.

Pressure on the shares followed Viking's presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on 14 September (Investing.com, 14 September 2026). Management discussed progress on the VK2735 obesity programme alongside risks around tolerability, pricing and policy. The two Phase III VANQUISH trials remain fully enrolled, with data expected in the second half of 2027 (TradingView, 15 September 2026).

VKTX fell again on 15 September during a broader equity-market decline, although healthcare remained comparatively resilient after gaining more than 11% over the previous 90 days (Benzinga, 15 September 2026). Investors are now awaiting results from a completed VK2735 maintenance-dosing study due this quarter, which could show whether less frequent dosing maintains weight-loss outcomes.

Third-party Viking Therapeutics outlook: VK2735 trials

As of 16 September 2026, third-party Viking Therapeutics stock predictions vary widely.

MarketBeat (consensus target)

MarketBeat records a $96.62 consensus price target as of 20 August 2026, alongside a ‘Moderate Buy’ consensus rating. The figure combines analyst estimates based on different assumptions about clinical development and commercial execution (MarketBeat, 20 August 2026).

Investing.com (analyst consensus)

Investing.com places the average 12-month target at $92.40 as of 11 September 2026. The dataset covers 19 analysts and reflects differing views on the development path for VK2735 (Investing.com, 11 September 2026).

Zacks Investment Research (consensus overview)

Zacks Investment Research reports a $91.76 average target as of 9 September 2026, based on 17 analyst estimates ranging from $35 to $125. The spread reflects different valuation assumptions for Viking’s obesity and metabolic-disease pipeline (Zacks, 9 September 2026).

Public.com (analyst consensus)

Public.com lists a $99.57 Wall Street analyst target as of 15 September 2026. The figure aggregates forward estimates and can vary depending on the analysts and methodologies included (Public.com, 15 September 2026).

Barron's (ratings survey)

Barron's shows analyst targets ranging from $65 to $125 as of 15 September 2026. The range reflects different assumptions around clinical results, regulatory pathways and potential market entry (Barron's, 15 September 2026).

Takeaway: Consensus captures dated 20 August–15 September 2026 range from $91.76 to $99.57, while individual estimates across the sources above span $35–$125. Differences in clinical, regulatory and commercial assumptions help explain the spread.

Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.

VKTX stock price: technical overview

As of 2.02pm UTC on 16 September 2026, the VKTX stock price trades at $29.89, close to the session low of $29.76 and below its 20-, 50-, 100- and 200-day simple moving averages (SMAs), at about $33.20, $34.40, $33 and $33.40, respectively. The 20-day SMA also sits below the 50-day SMA.

The 14-day relative strength index (RSI) reads 36.5, below its neutral midpoint but above the commonly used oversold threshold of 30. The average directional index (ADX) at 13.2 points to limited trend strength, while MACD is negative at −0.85. The Hull moving average (9) sits near $30.

The classic pivot stands at $33.44, with R1 at $35.60 and R2 at $38.42. The 20-day SMA near $33.20 and 50-day SMA near $34.40 provide further overhead reference levels. Below the current price, S2 sits at $28.46. S1 at $30.62 and the 200-day SMA near $33.40 are both currently above the market (TradingView, 16 September 2026).

Technical indicators can give mixed signals and do not predict future price movements. This analysis is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any instrument.

Viking Therapeutics (VKTX): Capital.com analyst view

Viking Therapeutics shares have seen notable swings in 2026, from around $32.53 in late July to a session low of $29.76 by mid-September. That period included conference appearances and clinical updates on VK2735, which Viking is developing in injectable and oral forms.

Positive trial data, progress through late-stage development or evidence that less frequent dosing remains effective could support expectations for VK2735 and the share price. Weaker-than-expected results, tolerability concerns, manufacturing problems or regulatory setbacks could weigh on both.

Biotech-sector performance and broader market risk appetite can influence VKTX too. Stronger sentiment towards clinical-stage biotech companies could support the shares, while wider equity-market weakness may put pressure on them even without company-specific news.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Past performance is not a reliable indicator of future results.

Summary – Viking Therapeutics 2026

As of 2.02pm UTC on 16 September 2026, Viking Therapeutics traded at $29.89, within a $29.76–$30.75 intraday range.
TradingView-derived indicators place VKTX below its main moving averages, while RSI at 36.5 sits below its neutral midpoint and ADX at 13.2 points to limited trend strength.
Price drivers include progress in the VK2735 obesity programme, clinical and execution risks, and wider biotech and equity-market conditions.
Viking says the Phase III VANQUISH studies for injectable VK2735 are fully enrolled, with results expected in the second half of 2027.

Past performance is not a reliable indicator of future results.

FAQ

Who owns the most Viking Therapeutics stock?

FMR LLC was Viking Therapeutics’ largest disclosed institutional shareholder as of 30 June 2026, holding about 6.3 million shares, or roughly 5.4% of the company. BlackRock and Vanguard were among the other large institutional holders. Ownership can change as funds adjust their positions, so these figures represent reported holdings rather than a permanent ownership structure. Viking also has a sizeable proportion of shares held by other institutions and public investors.

What is the five-year Viking Therapeutics share price forecast?

The article does not provide a five-year VKTX stock forecast. The analyst data reviewed focuses on 12-month targets, with consensus figures between $91.76 and $99.57 and individual estimates ranging from $35 to $125. Over a five-year period, VKTX could be influenced by clinical results, regulatory decisions, commercial progress and competition in obesity treatments. Those factors make longer-term forecasts particularly uncertain and subject to substantial revision.

Is Viking Therapeutics a good stock to buy?

Whether Viking Therapeutics is a good stock to buy depends partly on how an investor views its clinical pipeline and the risks attached to drug development. Positive VK2735 trial results or progress towards approval could support the shares, while weaker data, tolerability concerns, manufacturing issues or regulatory setbacks could weigh on them. Analyst targets currently vary widely, highlighting the uncertainty around future outcomes. This article does not provide a recommendation to buy or sell VKTX.

Could Viking Therapeutics stock go up or down?

Viking Therapeutics shares could move in either direction as new clinical and market information emerges. Positive VK2735 trial results, successful late-stage development or evidence supporting less frequent dosing could lift expectations for the programme and potentially the share price. Weaker results, delays, tolerability issues or regulatory setbacks could have the opposite effect. Broader biotech sentiment and equity-market risk appetite may also influence VKTX, even when there is little company-specific news.

Should I invest in Viking Therapeutics stock?

This article does not say whether you should invest in Viking Therapeutics. VKTX is a clinical-stage biotechnology stock whose valuation depends heavily on future trial results and regulatory progress, both of which remain uncertain. Potential progress in VK2735 could support the shares, while disappointing data or development setbacks could weigh on them. Whether the stock suits an individual investor depends on factors such as financial objectives, investment horizon and tolerance for company-specific and sector risk.

Can I trade Viking Therapeutics CFDs on Capital.com?

Yes, you can trade Viking Therapeutics CFDs on Capital.com. Trading share CFDs lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.